Table 1.

Patient- and Transplant-related Characteristics and Post-transplant Outcomes.

Study	Study type and study period	n (Male sex)	Median (range) age, years	Regimen intensity	Median F/U, months	CR	OS	Relapse	NRM
Tsimberidou et al. 2006 [14]	Single institution (1975–2005)	17 (Male = 11)	60 (35–72)	MAC = 2 RIC = 15	NE	6%	75% In CR/CRu/PR (3-y)	21%	12%
Cwynarski et al. 2012 [31]	EBMT registry (1997–2007)	25 (Male = 15)	57 (31–70)	MAC = 7 RIC = 18	29%	NE	36% (3-y)	47% (3-y)	26% (3-y)
							In CR/Cru/PR 41% (3-y)		MAC = 43% RIC = 19% (3-y)
							In refractory disease 17% (3-y)
Rozovski et al. 2015 [30]	Single institution (1998–2011)	20 (NE)	58 (32–72)	MAC = 6 RIC = 14	45	35%	36% (2-y) 0 (5-y)	NE	NE
Kharfan-Dabaja et al. 2017 [29]	Single institution (2008–2016)	10 (Male = 5)	63 (50–74)	MAC = 7 RIC = 3	46	70%	50% (4-y)	10% (4-y)	40% (4-y)

Note. F/U= follow up; CR = complete remission; Cru = complete remission undetermined; EBMT = European Society for Blood and Marrow Transplantation; MAC = myeloablative conditioning; mo = month; n = number of patients; NE = no extractable/not available data; NRM = non-relapse mortality; OS = overall survival; PR = partial response; RIC = reduced intensity conditioning; y = year.